New findings suggest that popular GLP-1 drugs, widely prescribed for weight loss and type 2 diabetes, may significantly influence a patient's risk of developing certain cancers. This is mainly for the better.
A comprehensive review of medical records has uncovered a compelling link. It found that the use of GLP-1 agonists - such as Ozempic, Wegovy, Mounjaro, and Zepbound - is associated with a reduced likelihood of being diagnosed with several types of cancer. However, the research also flags a potential, though unproven, increase in the risk for kidney cancer.
The Ground-Breaking Study
Researchers in the United States analysed a decade's worth of medical data. They compared over 43,000 users of GLP-1 medications with a matched group of non-users. All participants in the study were considered at risk for obesity-related cancers. The results, published in the prestigious journal JAMA Oncology, showed a notable difference. For every 1,000 people each year:
- 13.6 GLP-1 users were diagnosed with one of 14 obesity-related cancers.
- 16.6 non-users were diagnosed with the same cancers.
After adjusting for individual risk factors, the analysis concluded that people taking GLP-1 drugs had an overall cancer risk that was 17% lower. This was compared to those not taking the medication.
Which Cancer Risks Were Reduced?
The study highlighted particularly significant reductions in the risk for specific cancers among users of these popular drugs. The most substantial findings include:
- A 47% lower risk of developing ovarian cancer.
- A 31% lower risk of developing meningioma, a common type of brain tumour.
- A 25% lower risk of developing endometrial cancer.
A Note of Caution on Kidney Cancer
While the overall picture was positive, the study did associate GLP-1 drugs with a slight increase in the risk for kidney cancer.
Crucially, the researchers noted that this increase was not statistically significant. This means the observed link could be down to chance. However, the authors pointed out that this isn't the first time such a connection has been suggested. An earlier study also found a potential link between GLP-1 drugs for diabetes and a higher risk of kidney cancer.
Is It the Drug or the Weight Loss?
It is important to understand that this was an observational study. This type of study can identify correlations but cannot prove a direct cause-and-effect relationship.
Researchers cannot definitively say whether the reduced cancer risk is a direct result of the GLP-1 medications themselves. It could also be an indirect benefit of the significant weight loss these drugs induce. Obesity is a well-established risk factor for many types of cancer. So, any intervention that leads to weight loss could theoretically lower that risk.
Despite this limitation, the implications are vast. The study's authors concluded that more than 137 million individuals in the US are currently eligible for GLP-1 therapies. Therefore, even modest changes in cancer risk could have substantial public health implications.
Further research, including clinical trials, will be needed. These will help untangle these complex relationships and provide definitive answers. This is especially true for the millions of people using these transformative medications worldwide.